Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European group for blood and marrow transplantation

J. A. Snowden, R. Saccardi, M. Allez, S. Ardizzone, R. Arnold, R. Cervera, C. Denton, C. Hawkey, M. Labopin, G. Mancardi, R. Martin, J. J. Moore, J. Passweg, C. Peters, M. Rabusin, M. Rovira, J. M. Van Laar, D. Farge

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.

Original languageEnglish
Pages (from-to)770-790
Number of pages21
JournalBone Marrow Transplantation
Volume47
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Blood Group Antigens
Autoimmune Diseases
Transplantation
Bone Marrow
Guidelines
Biological Therapy
Accreditation
Insurance Benefits
Patient Safety
Group Psychotherapy
Patient Selection
Registries
Consensus
Research Design
Joints
Economics
Safety
Therapeutics

Keywords

  • allogeneic
  • autoimmune diseases
  • autologous
  • guidelines
  • haematopoietic SCT
  • recommendations

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Haematopoietic SCT in severe autoimmune diseases : Updated guidelines of the European group for blood and marrow transplantation. / Snowden, J. A.; Saccardi, R.; Allez, M.; Ardizzone, S.; Arnold, R.; Cervera, R.; Denton, C.; Hawkey, C.; Labopin, M.; Mancardi, G.; Martin, R.; Moore, J. J.; Passweg, J.; Peters, C.; Rabusin, M.; Rovira, M.; Van Laar, J. M.; Farge, D.

In: Bone Marrow Transplantation, Vol. 47, No. 6, 06.2012, p. 770-790.

Research output: Contribution to journalArticle

Snowden, JA, Saccardi, R, Allez, M, Ardizzone, S, Arnold, R, Cervera, R, Denton, C, Hawkey, C, Labopin, M, Mancardi, G, Martin, R, Moore, JJ, Passweg, J, Peters, C, Rabusin, M, Rovira, M, Van Laar, JM & Farge, D 2012, 'Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European group for blood and marrow transplantation', Bone Marrow Transplantation, vol. 47, no. 6, pp. 770-790. https://doi.org/10.1038/bmt.2011.185
Snowden, J. A. ; Saccardi, R. ; Allez, M. ; Ardizzone, S. ; Arnold, R. ; Cervera, R. ; Denton, C. ; Hawkey, C. ; Labopin, M. ; Mancardi, G. ; Martin, R. ; Moore, J. J. ; Passweg, J. ; Peters, C. ; Rabusin, M. ; Rovira, M. ; Van Laar, J. M. ; Farge, D. / Haematopoietic SCT in severe autoimmune diseases : Updated guidelines of the European group for blood and marrow transplantation. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 6. pp. 770-790.
@article{53815b6d312841698bd217f083d3f634,
title = "Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European group for blood and marrow transplantation",
abstract = "In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.",
keywords = "allogeneic, autoimmune diseases, autologous, guidelines, haematopoietic SCT, recommendations",
author = "Snowden, {J. A.} and R. Saccardi and M. Allez and S. Ardizzone and R. Arnold and R. Cervera and C. Denton and C. Hawkey and M. Labopin and G. Mancardi and R. Martin and Moore, {J. J.} and J. Passweg and C. Peters and M. Rabusin and M. Rovira and {Van Laar}, {J. M.} and D. Farge",
year = "2012",
month = "6",
doi = "10.1038/bmt.2011.185",
language = "English",
volume = "47",
pages = "770--790",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Haematopoietic SCT in severe autoimmune diseases

T2 - Updated guidelines of the European group for blood and marrow transplantation

AU - Snowden, J. A.

AU - Saccardi, R.

AU - Allez, M.

AU - Ardizzone, S.

AU - Arnold, R.

AU - Cervera, R.

AU - Denton, C.

AU - Hawkey, C.

AU - Labopin, M.

AU - Mancardi, G.

AU - Martin, R.

AU - Moore, J. J.

AU - Passweg, J.

AU - Peters, C.

AU - Rabusin, M.

AU - Rovira, M.

AU - Van Laar, J. M.

AU - Farge, D.

PY - 2012/6

Y1 - 2012/6

N2 - In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.

AB - In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.

KW - allogeneic

KW - autoimmune diseases

KW - autologous

KW - guidelines

KW - haematopoietic SCT

KW - recommendations

UR - http://www.scopus.com/inward/record.url?scp=84862184679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862184679&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.185

DO - 10.1038/bmt.2011.185

M3 - Article

C2 - 22002489

AN - SCOPUS:84862184679

VL - 47

SP - 770

EP - 790

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -